| Sanofi Looks Beyond Its Own Walls for Innovation The Burrill Report submits: Sanofi-Aventis (SNY) is searching for an edge. Like other big pharmas, the company is undergoing a push to shift the balance between its internal and external research and development and is increasingly looking outside its own walls for breakthrough ideas.At the BIO International Convention in Chicago at the start of May, the Paris-Based pharmaceutical company announced it had joined the Massachusetts Life Sciences Center’s Corporate Consortium Program. The Center, a quasi-public agency, is charged with implementing a ten-year, $1 billion Life Sciences Initiative for the state. Under the agreement, Sanofi is paying $500,000 for a two-year, non-voting membership. The funds will be used in the center’s Accelerator Program, which makes loans to early-stage Massachusetts life sciences companies performing translational science and research. What Sanofi gets in return is an early peek at these promising companies and their technologies.We spoke [podcast] to Paul Chew, U.S. chief medical officer for Sanofi, about the agreement, changes to the company’s R&D structure, and why Big Pharma is increasingly looking beyond its own walls for innovation.Complete Story » seekingalpha.com |
Inverness Medical Innovations Changes Name to Alere (PR Newswire) Inverness Medical Innovations, Inc. , a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has changed its name to Alere Inc., after shareholders approved the name change at its Annual Meeting of Stockholders held on July 14, 2010. Â The Company also announced that it expects its NYSE stock symbol to change from "IMA" to "ALR" effective Monday, July 19, 2010. us.rd.yahoo.com |
Missouri Voters Oppose Mandatory Health Insurance Voters in Missouri overwhelmingly opposed requiring people to buy health insurance, in a largely symbolic slap at the Obama administration's health overhaul. online.wsj.com |
Artistry Crème LuXury - Video Creme LuXury Combats Intrinsic Causes of Skin Aging with Industry Leading Technology feedproxy.google.com |
FDA Again Denies Approval for Long-Acting Byetta The FDA again declined to approve a long-acting version of diabetes drug Byetta, currently sold by Amylin Pharmaceuticals Inc. and Eli Lilly, substantially delaying an approval that was widely expected this week. online.wsj.com |